Literature DB >> 16266992

Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.

Victoria Emuss1, Mathew Garnett, Clive Mason, Richard Marais.   

Abstract

The protein kinase B-RAF is mutated in approximately 8% of human cancers. Here we show that presumptive mutants of the closely related kinase, C-RAF, were detected in only 4 of 545 (0.7%) cancer cell lines. The activity of two of the mutated proteins is not significantly different from that of wild-type C-RAF and these variants may represent rare human polymorphisms. The basal and B-RAF-stimulated kinase activities of a third variant are unaltered but its activation by RAS is significantly reduced, suggesting that it may act in a dominant-negative manner to modulate pathway signaling. The fourth variant has elevated basal kinase activity and is hypersensitive to activation by RAS but does not transform mammalian cells. Furthermore, when we introduce the equivalent of the most common cancer mutation in B-RAF (V600E) into C-RAF, it only has a weak effect on kinase activity and does not convert C-RAF into an oncogene. This lack of activation occurs because C-RAF lacks a constitutive charge within a motif in the kinase domain called the N-region. This fundamental difference in RAF isoform regulation explains why B-RAF is frequently mutated in cancer whereas C-RAF mutations are rare.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16266992     DOI: 10.1158/0008-5472.CAN-05-1683

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  60 in total

Review 1.  Signal control through Raf: in sickness and in health.

Authors:  Jihan K Osborne; Elma Zaganjor; Melanie H Cobb
Journal:  Cell Res       Date:  2011-12-06       Impact factor: 25.617

2.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

3.  Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

Authors:  Banibrata Sen; Shaohua Peng; Ximing Tang; Heidi S Erickson; Hector Galindo; Tuhina Mazumdar; David J Stewart; Ignacio Wistuba; Faye M Johnson
Journal:  Sci Transl Med       Date:  2012-05-30       Impact factor: 17.956

Review 4.  Pathway perturbations in signaling networks: Linking genotype to phenotype.

Authors:  Yongsheng Li; Daniel J McGrail; Natasha Latysheva; Song Yi; M Madan Babu; Nidhi Sahni
Journal:  Semin Cell Dev Biol       Date:  2018-05-10       Impact factor: 7.727

Review 5.  Selective Raf inhibition in cancer therapy.

Authors:  Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

Review 6.  Mouse models for BRAF-induced cancers.

Authors:  C Pritchard; L Carragher; V Aldridge; S Giblett; H Jin; C Foster; C Andreadi; T Kamata
Journal:  Biochem Soc Trans       Date:  2007-11       Impact factor: 5.407

Review 7.  Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.

Authors:  Matthew Holderfield; Marian M Deuker; Frank McCormick; Martin McMahon
Journal:  Nat Rev Cancer       Date:  2014-07       Impact factor: 60.716

Review 8.  Histiocytic neoplasms in the era of personalized genomic medicine.

Authors:  Benjamin H Durham; Eli L Diamond; Omar Abdel-Wahab
Journal:  Curr Opin Hematol       Date:  2016-07       Impact factor: 3.284

9.  Activation loop phosphorylation regulates B-Raf in vivo and transformation by B-Raf mutants.

Authors:  Martin Köhler; Michael Röring; Björn Schorch; Katharina Heilmann; Natalie Stickel; Gina J Fiala; Lisa C Schmitt; Sandra Braun; Sophia Ehrenfeld; Franziska M Uhl; Thorsten Kaltenbacher; Florian Weinberg; Sebastian Herzog; Robert Zeiser; Wolfgang W Schamel; Hassan Jumaa; Tilman Brummer
Journal:  EMBO J       Date:  2015-12-10       Impact factor: 11.598

Review 10.  Main roads to melanoma.

Authors:  Giuseppe Palmieri; Mariaelena Capone; Maria Libera Ascierto; Giusy Gentilcore; David F Stroncek; Milena Casula; Maria Cristina Sini; Marco Palla; Nicola Mozzillo; Paolo A Ascierto
Journal:  J Transl Med       Date:  2009-10-14       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.